First Bank & Trust grew its stake in shares of GlaxoSmithKline plc (NYSE:GSK) by 5.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 47,043 shares of the pharmaceutical company’s stock after acquiring an additional 2,503 shares during the quarter. GlaxoSmithKline comprises about 1.3% of First Bank & Trust’s portfolio, making the stock its 17th biggest holding. First Bank & Trust’s holdings in GlaxoSmithKline were worth $1,669,000 as of its most recent filing with the SEC.
Several other large investors also recently added to or reduced their stakes in GSK. 1st Global Advisors Inc. lifted its position in shares of GlaxoSmithKline by 0.4% during the 2nd quarter. 1st Global Advisors Inc. now owns 5,271 shares of the pharmaceutical company’s stock worth $227,000 after buying an additional 19 shares during the last quarter. King Luther Capital Management Corp lifted its position in shares of GlaxoSmithKline by 1.0% during the 2nd quarter. King Luther Capital Management Corp now owns 5,432 shares of the pharmaceutical company’s stock worth $234,000 after buying an additional 55 shares during the last quarter. PagnatoKarp Partners LLC lifted its position in shares of GlaxoSmithKline by 1.4% during the 2nd quarter. PagnatoKarp Partners LLC now owns 5,812 shares of the pharmaceutical company’s stock worth $253,000 after buying an additional 80 shares during the last quarter. Peapack Gladstone Financial Corp lifted its position in shares of GlaxoSmithKline by 1.0% during the 2nd quarter. Peapack Gladstone Financial Corp now owns 11,740 shares of the pharmaceutical company’s stock worth $506,000 after buying an additional 115 shares during the last quarter. Finally, Quadrant Capital Group LLC lifted its position in shares of GlaxoSmithKline by 3.5% during the 2nd quarter. Quadrant Capital Group LLC now owns 4,345 shares of the pharmaceutical company’s stock worth $162,000 after buying an additional 148 shares during the last quarter. Hedge funds and other institutional investors own 9.80% of the company’s stock.
GlaxoSmithKline plc (GSK) traded down $0.06 during trading on Thursday, reaching $38.09. The company’s stock had a trading volume of 3,328,927 shares, compared to its average volume of 6,219,854. The company has a quick ratio of 0.44, a current ratio of 0.64 and a debt-to-equity ratio of 2.96. The company has a market capitalization of $92,850.00, a P/E ratio of 29.07, a PEG ratio of 2.17 and a beta of 0.97. GlaxoSmithKline plc has a 1 year low of $34.52 and a 1 year high of $44.53.
GlaxoSmithKline (NYSE:GSK) last posted its earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.85 EPS for the quarter, beating the consensus estimate of $0.84 by $0.01. GlaxoSmithKline had a return on equity of 115.30% and a net margin of 7.79%. equities research analysts forecast that GlaxoSmithKline plc will post 2.9 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Thursday, January 11th. Shareholders of record on Friday, November 10th were given a $0.5037 dividend. The ex-dividend date was Thursday, November 9th. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.49. This represents a $2.01 annualized dividend and a yield of 5.29%. GlaxoSmithKline’s dividend payout ratio (DPR) is currently 155.73%.
Several brokerages recently weighed in on GSK. Zacks Investment Research upgraded GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research report on Wednesday, October 18th. JPMorgan Chase & Co. restated a “neutral” rating on shares of GlaxoSmithKline in a research report on Wednesday, October 18th. Bank of America downgraded GlaxoSmithKline from a “buy” rating to a “neutral” rating in a research report on Thursday, October 26th. UBS Group restated a “buy” rating on shares of GlaxoSmithKline in a research report on Monday. Finally, Barclays upgraded GlaxoSmithKline from an “equal weight” rating to an “overweight” rating in a research report on Tuesday. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $38.57.
In other news, major shareholder Plc Glaxosmithkline bought 428,571 shares of the company’s stock in a transaction on Monday, November 6th. The stock was purchased at an average cost of $14.00 per share, for a total transaction of $5,999,994.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 10.00% of the stock is currently owned by company insiders.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.